Meeting
2020 Genitourinary Cancers Symposium
Molecular characteristics of renal cell carcinoma (RCC) risk groups from JAVELIN Renal 101.
Authors
Toni K. Choueiri
The Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Boston, MA
Toni K. Choueiri , John B. A. G. Haanen , James M. G. Larkin , Brian I. Rini , Laurence Albiges , Robert J. Motzer , Alessandra di Pietro , Xinmeng Jasmine Mu , Keith A. Ching , Subramanian Hariharan , Paul B. Robbins
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Renal Cell Cancer
Track
Renal Cell Cancer
Sub Track
Tumor Biology, Biomarkers, and Pathology
Clinical Trial Registration Number
NCT02684006
Citation
J Clin Oncol 38, 2020 (suppl 6; abstr 744)
Abstract #
744
Poster Bd #
J20
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Genitourinary Cancers Symposium
Preclinical testing of a novel PD-L1 inhibitor for the treatment of renal cell carcinoma.
First Author: Michelle Hsu
Poster
2022 ASCO Genitourinary Cancers Symposium
Assessing physician prescribing behaviors in first-line (1L) advanced renal cell carcinoma (aRCC): A case-based study.
First Author: Ajeet Gajra
Poster
2022 ASCO Gastrointestinal Cancers Symposium
The immune impact of PI3K-AKT pathway inhibition in colorectal cancer.
First Author: Maliha Nusrat
Poster
2021 ASCO Annual Meeting
Efficacy of avelumab + axitinib (A + Ax) versus sunitinib (S) by IMDC risk group in advanced renal cell carcinoma (aRCC): Extended follow-up results from JAVELIN Renal 101.
First Author: John B. A. G. Haanen